Insider Selling: Craig A. Wheeler Unloads 2,209 Shares of Momenta Pharmaceuticals Stock (MNTA)
Momenta Pharmaceuticals (NASDAQ:MNTA) President Craig A. Wheeler unloaded 2,209 shares of Momenta Pharmaceuticals stock on the open market in a transaction dated Monday, August 25th. The shares were sold at an average price of $11.45, for a total transaction of $25,293.05. Following the sale, the president now directly owns 368,309 shares in the company, valued at approximately $4,217,138. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of research firms have recently commented on MNTA. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, June 5th. They set a “buy” rating and a $17.00 price target on the stock. Analysts at Goldman Sachs initiated coverage on shares of Momenta Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $19.20.
Momenta Pharmaceuticals (NASDAQ:MNTA) traded up 1.20% during mid-day trading on Tuesday, hitting $11.82. 245,624 shares of the company’s stock traded hands. Momenta Pharmaceuticals has a one year low of $9.85 and a one year high of $19.90. The stock has a 50-day moving average of $11.24 and a 200-day moving average of $12.70. The company’s market cap is $608.5 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings data on Thursday, July 31st. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.46) by $0.05. The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.22 million. During the same quarter last year, the company posted ($0.57) earnings per share. Momenta Pharmaceuticals’s revenue was up 151.1% compared to the same quarter last year. On average, analysts predict that Momenta Pharmaceuticals will post $-1.14 earnings per share for the current fiscal year.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.